Our Mission

Our Mission

Milestones en route to an onchocerciasis vaccine
Colours identify different work packages. The relative in each work package is indicated by circle area. Activity 3, funded by USA NIH grant number 2R01A1078314-06A1. https://projectreporter.nih.gov/project_info_details.cfm?aid=9308538&icde=33588104

The way forward for vaccine development

TOVA Initiative has set its goal to take at least one vaccine candidate to Phase I trials by 2020. To do this the following tasks have been identified:

  1. Mathematical modelling of vaccine efficacy design of control programmes, and cost-effectiveness.
  2. Systems analysis to identify specific molecular interactions between parasite and host to idenify immne correlates of protection  and assist formulation of the vaccine for maximum efficacy, and avoid adverse reactions.
  3. Efficacy trials using the O ochengi cattle model under conditions of natural exposure.
  4. Process development for human recombinant vaccine production or synthetic vaccines, including formulation, assay development, quality control and stability.
  5. Technology transfer for cGMP manufacturing of vaccines.
  6. GLP toxicology testing of vaccines.
  7. Regulatory filing.
  8. Phase I, first-in-human safety trials in developed and in endemic countries.
  9. Assessment of immune responses of children up to 9 years age who are exposed to O volvulus infections in preparation for phase II trials